BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $140 from $135 and keeps a Buy rating on the shares. The company’s Q1 sales beat was driven primarily by a record Zio AT quarter, with continued share gains following a disruption in a competitor’s MCT business in Q4 and contribution from new account openings, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Irhythm Technologies: Strong Performance and Growth Potential Justify Buy Rating
- iRhythm price target lowered to $139 from $152 at Canaccord
- Irhythm Technologies: Strong Q1 2025 Performance and Raised Price Target Reinforce Buy Rating
- Strong Commercial Momentum and Strategic Partnerships Drive Buy Rating for Irhythm Technologies
- Wells upgrades iRhythm to Overweight on strong business trends